Landmark trials, including the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) and Irbesartan Diabetic Nephropathy Trial (IDNT) studies, demonstrated that ARBs reduce progression to end-stage kidney disease (ESKD) in type 2 diabetes mellitus (T2DM) patients with proteinuria (112). Here, AGT is linked to type 2 diabetes mellitus.